Navigation Links
Infinity Bio-Energy Ltd. Announces 2008 Annual General Meeting
Date:6/16/2008

SAO PAULO, Brazil, June 17 /PRNewswire/ -- Pursuant to the BDR offering and BOVESPA Listing announcement released on June 06, 2008, Infinity Bio-Energy Ltd. has called a shareholders' meeting on June 25, 2008 at 10:00 a.m (Sao Paulo time) to approve new bye-laws conforming to Novo Mercado Standards, the election and re-election of new board directors and the presentation of auditors' reports and financial statements and other matters.

Novo Mercado is a special segment of the Brazilian Stock Exchange (BOVESPA) which requires high standards of Corporate Governance. Notwithstanding that the BDR offering does not demand the same Corporate Governance levels, the Company intends to incorporate the Novo Mercado standards, being governed by the proposed bye-laws. In order to achieve these standards, the Company invites all shareholders to vote on the 2008 Annual General Meeting.

The agenda is described below:

Notice

YOU ARE HEREBY NOTIFIED that the 2008 Annual General Meeting of the Company
will be held at Rua Funchal, 418, 22nd floor, Sao Paulo, SP, Brazil, on:

June 25, 2008 at 10:00 a.m. (Sao Paulo time)

AGENDA

1. Elect a Chairman of the General Meeting, if necessary.

2. Read Notice convening this meeting.

3. Minutes of the last General Meeting to be read and confirmed.

4. Presentation of Auditors' Report and Financial Statements for the

year ended March 31, 2008.

5. Presentation of Directors' Report to the Shareholders.

6. Appoint BDO as Auditor of the Company until the close of the next

Annual General Meeting and authorize the Board of Directors to

determine the remuneration of the Auditor.

7. Consider the election of Eduardo Bom Angelo, Alberto Mendes Tepedino

and Dimitri Marriette Henri Pauwels as Class III Directors, and

authorize them to appoint Alternate Directors as and when they deem

fit.

8. Consider the re-election of John Walter and Dominic DiMarco as Class

II Directors, and authorize them to appoint Alternate Directors as

and when they deem fit.

9. Consider to redesign Andrew Lipman and Sergio Thompson-Flores as

Class II Directors, and authorize them to appoint Alternate

Directors as and when they deem fit.

10. Consider that the fees payable to the Directors will be determined

by the Compensation Committee.

11. Consider and, if thought fit, approve the recommendation of the

Board of Directors to amend the existing Bye-Laws of the Company in

the manner specified in the blacklined version of the Bye-Laws, to

be effective upon and subject to consummation of the offer of the

Brazilian DRs.

12. Consider any other business, which may properly come before the

meeting.

The proxy and amended bye-laws have been sent to the shareholders and are also available on the Company's website at http://www.infinitybio.com.br.


'/>"/>
SOURCE Infinity Bio-Energy Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Elekta Announces Elekta Infinity - a New System for Faster and More Precise Treatment of Cancer Tumors
2. EnzySurge, Maker of DermaStream(TM), Announces the Formation of its Scientific Advisory Board
3. Haemonetics Announces Launch of Faster Plasma Collection Protocol
4. Meritage Pharma, Inc. Announces Company Formation and $22.5M Series A Financing
5. Angiotech announces market launch of Quill(TM) SRS MONODERM(TM)
6. Exelixis Announces June 19 Webcast of Presentation at the William Blair 28th Annual Growth Stock Conference
7. Villa St. Benedict Announces New Web Site
8. BioNeutral Announces a BREAKTHROUGH in the Fight Against Bioterrorism
9. Indevus Announces Management Changes
10. Chindex International, Inc. Announces Fiscal 2008 Year End and Fourth Quarter Results
11. Cell Therapeutics, Inc. Announces Issuance of 2011 Convertible Senior Notes and Common Stock Warrants to a Single Institutional Investor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... -- Kurzlehrgang mit Fokus auf Assay ... legt metaproteomische Analyse des Darm-Mikrobioms bei Säuglingen dar   ... ... Yoav Peretz , Scientific Director bei ImmuneCarta, einen Kurzlehrgang ... Nachweis intrazellulärer Zytokine bei adoptiven Zelltherapie-Studien im Rahmen der ...
(Date:2/18/2017)... ... 2017 , ... A leader in science-based, age-fighting skincare products, ... is proud to introduce its Age-Defying Night Cream, NeriumAD™ Formula, Age-Defying Day Cream, ... Hong Kong. The luxury skincare products contain innovative ingredients that fight the signs ...
(Date:2/17/2017)... , February 17, 2017 ... Market by Product (Consumables, Service), Type (Safety, Efficacy, ... Development, Drug Discovery and Development, Disease-Risk) - Global ... is projected to reach USD 53.34 Billion by ... at a CAGR of 13.8% during the forecast ...
(Date:2/17/2017)... Mass. , Feb. 17, 2017  If ... small tumor had a mutation-conferring resistance to chemotherapy, ... Recently, genomics research has focused on finding these ... or even from circulating tumor DNA in blood ... new oncology therapeutics. Unfortunately, however, detecting ...
Breaking Biology Technology:
(Date:2/10/2017)... Research and Markets has announced the addition of ... Commercial Aspects" to their offering. ... Biomarkers play an important ... selection of treatment as well for monitoring the results. There ... modern medicine. Biochip/microarray technologies and next generation sequencing are also ...
(Date:2/8/2017)... 8, 2017 About Voice Recognition Biometrics Voice ... it against a stored voiceprint template. Acoustic features ... and tone are compared to distinguish between individual ... as most PCs already have a microphone and ... recognition biometrics are most likely to be deployed ...
(Date:2/8/2017)... NEW YORK , Feb. 7, 2017 Report ... ... and should reach $11.4 billion by 2021, growing at a ... Report Includes - An overview of the global markets for ... from 2015, estimates for 2016, and projections of compound annual ...
Breaking Biology News(10 mins):